Day One Biopharmaceuticals Enters Exclusive Licensing Agreement With MabCare Therapeutics For MTX-13; IND Cleared By FDA In April 2024, Targets PTK7 In Adult And Pediatric Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Day One Biopharmaceuticals has entered an exclusive licensing agreement with MabCare Therapeutics for MTX-13, a drug targeting PTK7 in adult and pediatric solid tumors. The IND for MTX-13 was cleared by the FDA in April 2024.
June 18, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Day One Biopharmaceuticals has secured an exclusive licensing agreement with MabCare Therapeutics for MTX-13, which targets PTK7 in solid tumors. The FDA cleared the IND for MTX-13 in April 2024, potentially accelerating its development and market entry.
The exclusive licensing agreement and FDA clearance for the IND of MTX-13 are significant milestones for Day One Biopharmaceuticals. These developments could accelerate the drug's development and market entry, potentially boosting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100